Lifevantage (NASDAQ:LFVN) Updates FY 2026 Earnings Guidance

Lifevantage (NASDAQ:LFVN) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.600-0.600 for the period, compared to the consensus earnings per share estimate of 0.670. The company issued revenue guidance of $185.0 million-$185.0 million, compared to the consensus revenue estimate of $193.0 million.

Lifevantage Price Performance

LFVN stock traded up $0.32 on Friday, reaching $5.34. 248,095 shares of the company were exchanged, compared to its average volume of 202,794. The firm has a market capitalization of $68.31 million, a PE ratio of 11.86 and a beta of 0.52. The stock’s fifty day moving average price is $4.71 and its 200 day moving average price is $5.79. Lifevantage has a 12 month low of $3.90 and a 12 month high of $15.00.

Lifevantage (NASDAQ:LFVN) last issued its earnings results on Wednesday, May 6th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.04). The firm had revenue of $43.72 million during the quarter, compared to the consensus estimate of $47.77 million. Lifevantage had a return on equity of 23.84% and a net margin of 2.94%. As a group, research analysts expect that Lifevantage will post 0.65 EPS for the current fiscal year.

Lifevantage Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 15th. Shareholders of record on Monday, June 1st will be given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 3.7%. This is a positive change from Lifevantage’s previous quarterly dividend of $0.05. The ex-dividend date is Monday, June 1st. Lifevantage’s dividend payout ratio (DPR) is currently 40.00%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Weiss Ratings cut Lifevantage from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday. Lake Street Capital downgraded shares of Lifevantage from a “buy” rating to a “hold” rating and set a $5.00 price target on the stock. in a research report on Thursday. Finally, Loop Capital set a $5.00 price target on shares of Lifevantage in a research report on Thursday, February 5th. Two analysts have rated the stock with a Hold rating, According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $5.00.

Insider Activity at Lifevantage

In other Lifevantage news, Director Judd Dayton bought 10,500 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was acquired at an average cost of $4.53 per share, with a total value of $47,565.00. Following the purchase, the director owned 80,359 shares in the company, valued at $364,026.27. This trade represents a 15.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders bought 38,207 shares of company stock valued at $178,585. Corporate insiders own 21.95% of the company’s stock.

Institutional Trading of Lifevantage

A number of large investors have recently bought and sold shares of LFVN. JPMorgan Chase & Co. boosted its position in Lifevantage by 870.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock worth $66,000 after acquiring an additional 4,499 shares during the last quarter. Franklin Resources Inc. acquired a new position in Lifevantage during the 4th quarter worth approximately $74,000. Jain Global LLC acquired a new position in Lifevantage during the 4th quarter worth approximately $76,000. Aristides Capital LLC acquired a new position in Lifevantage during the 4th quarter worth approximately $76,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Lifevantage during the 2nd quarter worth approximately $76,000. 35.32% of the stock is owned by institutional investors.

Lifevantage Company Profile

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.